Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thomas Powles
  • Robert J Motzer
  • Bernard Escudier
  • Sumanta Pal
  • Christian Kollmannsberger
  • Joanna Pikiel
  • Howard Gurney
  • Sun Young Rha
  • Se Hoon Park
  • Poul F Geertsen
  • Marine Gross-Goupil
  • Enrique Grande
  • Cristina Suarez
  • David W Markby
  • Alan Arroyo
  • Mark Dean
  • Toni K Choueiri
  • Daniel George
Vis graf over relationer

BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy.

METHODS: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy.

RESULTS: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32-0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47-0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45-0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42-1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07-0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21-1.52).

CONCLUSIONS: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind119
Udgave nummer6
Sider (fra-til)663-669
Antal sider7
ISSN0007-0920
DOI
StatusUdgivet - sep. 2018

ID: 56573513